
Andrea Schneider

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4633519/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome. Journal of Neurodevelopmental Disorders, 2022, 14, 23.	1.5	8
2	Case Report: Coexistence of Alzheimer-Type Neuropathology in Fragile X-Associated Tremor Ataxia Syndrome. Frontiers in Neuroscience, 2021, 15, 720253.	1.4	8
3	EEG Signal Complexity Is Reduced During Resting-State in Fragile X Syndrome. Frontiers in Psychiatry, 2021, 12, 716707.	1.3	5
4	Increased Pain Symptomatology Among Females vs. Males With Fragile X-Associated Tremor/Ataxia Syndrome. Frontiers in Psychiatry, 2021, 12, 762915.	1.3	6
5	Review of Autism Profiles and Response to Sertraline in Fragile X Syndrome-Associated Autism vs. Non-syndromic Autism; Next Steps for Targeted Treatment. Frontiers in Neurology, 2020, 11, 581429.	1.1	10
6	Characterization of the Metabolic, Clinical and Neuropsychological Phenotype of Female Carriers of the Premutation in the X-Linked FMR1 Gene. Frontiers in Molecular Biosciences, 2020, 7, 578640.	1.6	12
7	Women with Fragile X–associated Tremor/Ataxia Syndrome. Movement Disorders Clinical Practice, 2020, 7, 910-919.	0.8	13
8	<p>Rapidly Progressing Neurocognitive Disorder in a Male with FXTAS and Alzheimer's Disease</p> . Clinical Interventions in Aging, 2020, Volume 15, 285-292.	1.3	7
9	Elevated FMR1-mRNA and lowered FMRP – A double-hit mechanism for psychiatric features in men with FMR1 premutations. Translational Psychiatry, 2020, 10, 205.	2.4	20
10	Developmental aspects of FXAND in a man with the <i>FMR1</i> premutation. Molecular Genetics & Genomic Medicine, 2020, 8, e1050.	0.6	5
11	A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder. Frontiers in Psychiatry, 2019, 10, 810.	1.3	22
12	Metformin treatment in young children with fragile X syndrome. Molecular Genetics & Genomic Medicine, 2019, 7, e956.	0.6	39
13	Cognitive and behavioral improvement in adults with fragile X syndrome treated with metforminâ€ŧwo cases. Molecular Genetics & Genomic Medicine, 2019, 7, e00745.	0.6	21
14	Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS ONE, 2019, 14, e0226811.	1.1	52
15	Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study. Molecular Neurobiology, 2019, 56, 3702-3713.	1.9	28
16	Fragile X-Associated Neuropsychiatric Disorders (FXAND). Frontiers in Psychiatry, 2018, 9, 564.	1.3	132
17	Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers. Frontiers in Genetics, 2018, 9, 302.	1.1	4
18	Impact of FMR1 Premutation on Neurobehavior and Bioenergetics in Young Monozygotic Twins. Frontiers in Genetics, 2018, 9, 338.	1.1	17

#	Article	IF	CITATIONS
19	Computerized Cognitive Training in Children With Autism and Intellectual Disabilities: Feasibility and Satisfaction Study. JMIR Mental Health, 2018, 5, e40.	1.7	18
20	Fentanyl overdose in a female with the premutation and FXTAS. , 2018, 1, .		3
21	Clinical and molecular correlates in fragile X premutation females. ENeurologicalSci, 2017, 7, 49-56.	0.5	13
22	A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. Journal of Neurodevelopmental Disorders, 2017, 9, 26.	1.5	67
23	Broad autism spectrum and obsessive–compulsive symptoms in adults with the fragile X premutation. Clinical Neuropsychologist, 2016, 30, 929-943.	1.5	34
24	Warburg effect linked to cognitiveâ€executive deficits in <i>FMR1</i> premutation. FASEB Journal, 2016, 30, 3334-3351.	0.2	33
25	Psychiatric disorders among women with the fragile X premutation without children affected by fragile X syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 1139-1147.	1.1	21
26	The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions. Journal of Neurodevelopmental Disorders, 2016, 8, 35.	1.5	96
27	A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2016, 37, 619-628.	0.6	65
28	Aging in Fragile X Premutation Carriers. Cerebellum, 2016, 15, 587-594.	1.4	14
29	A feasibility trial of Cogmed working memory training in fragile X syndrome. Journal of Pediatric Genetics, 2015, 03, 147-156.	0.3	13
30	Psychosis and catatonia in fragile X: Case report and literature review. Intractable and Rare Diseases Research, 2015, 4, 139-146.	0.3	12
31	Methadone use in a male with the <i>FMRI</i> premutation and FXTAS. American Journal of Medical Genetics, Part A, 2015, 167, 1354-1359.	0.7	24
32	High functioning male with fragile X syndrome and fragile Xâ€associated tremor/ataxia syndrome. American Journal of Medical Genetics, Part A, 2015, 167, 2154-2161.	0.7	28
33	Preliminary Evidence to Support a "Boot Camp―Approach to Wheelchair Skills Training for Clinicians. Archives of Physical Medicine and Rehabilitation, 2015, 96, 1158-1161.	0.5	21
34	Fragile X–Associated Tremor/Ataxia Syndrome in a Man in His 30s. JAMA Neurology, 2015, 72, 1070.	4.5	26
35	Translational research guided by animal studies in Fragile X Disorders. Intractable and Rare Diseases Research, 2014, 3, 100-100.	0.3	0
36	Parent-delivered touchscreen intervention for children with fragile X syndrome. Intractable and Rare Diseases Research, 2014, 3, 166-177.	0.3	8

#	Article	IF	CITATIONS
37	Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases. Intractable and Rare Diseases Research, 2014, 3, 162-165.	0.3	34
38	Improving IQ measurement in intellectual disabilities using true deviation from population norms. Journal of Neurodevelopmental Disorders, 2014, 6, 16.	1.5	111
39	Case report: Dystonia in a fragile X carrier. Movement Disorders, 2014, 29, E4-5.	2.2	2
40	A family with two female siblings with compound heterozygous <i><scp>FMR1</scp></i> premutation alleles. Clinical Genetics, 2014, 85, 458-463.	1.0	3
41	Memantine Effects on Verbal Memory in Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): a Double-Blind Brain Potential Study. Neuropsychopharmacology, 2014, 39, 2760-2768.	2.8	36
42	Abnormal semantic processing in females with fragile Xâ€associated tremor/ataxia syndrome. Genes, Brain and Behavior, 2014, 13, 152-162.	1.1	10
43	The cognitive neuropsychological phenotype of carriers of the FMR1 premutation. Journal of Neurodevelopmental Disorders, 2014, 6, 28.	1.5	74
44	ERP abnormalities elicited by word repetition in fragile X-associated tremor/ataxia syndrome (FXTAS) and amnestic MCI. Neuropsychologia, 2014, 63, 34-42.	0.7	21
45	Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers. Brain Disorders & Therapy, 2014, 03, .	0.1	40
46	Memantine for Fragile X–Associated Tremor/Ataxia Syndrome. Journal of Clinical Psychiatry, 2014, 75, 264-271.	1.1	44
47	Fragile X–Associated Tremor/Ataxia Syndrome. JAMA Neurology, 2013, 70, 1022.	4.5	64
48	Fragile X syndrome: An aging perspective. Developmental Disabilities Research Reviews, 2013, 18, 68-74.	2.9	14
49	Phenotypes of hypofrontality in older female fragile x premutation carriers. Annals of Neurology, 2013, 74, n/a-n/a.	2.8	25
50	Electrocortical changes associated with minocycline treatment in fragile X syndrome. Journal of Psychopharmacology, 2013, 27, 956-963.	2.0	92
51	Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles. NeuroImage, 2013, 65, 288-298.	2.1	31
52	A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2013, 34, 147-155.	0.6	212
53	Neural Substrates of Executive Dysfunction in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): a Brain Potential Study. Cerebral Cortex, 2013, 23, 2657-2666.	1.6	28
54	Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers. Current Psychiatry Reviews, 2013, 9, 65-71.	0.9	21

#	Article	IF	CITATIONS
55	Psychiatric Features in High-Functioning Adult Brothers With Fragile X Spectrum Disorders. primary care companion for CNS disorders, The, 2013, 15, .	0.2	8
56	Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers. Current Psychiatry Reviews, 2013, 9, 65-71.	0.9	10
57	Early Intervention Combined with Targeted Treatment Promotes Cognitive and Behavioral Improvements in Young Children with Fragile X Syndrome. Case Reports in Genetics, 2012, 2012, 1-4.	0.1	39
58	Prepulse inhibition in patients with fragile X-associated tremor ataxia syndrome. Neurobiology of Aging, 2012, 33, 1045-1053.	1.5	17
59	Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS). Journal of Neurodevelopmental Disorders, 2012, 4, 2.	1.5	47
60	Male Carriers of the FMR1 Premutation Show Altered Hippocampal-Prefrontal Function During Memory Encoding. Frontiers in Human Neuroscience, 2012, 6, 297.	1.0	25
61	A fragile X sibship from a consanguineous family with a compound heterozygous female and partially methylated full mutation male. American Journal of Medical Genetics, Part A, 2012, 158A, 1221-1224.	0.7	7
62	Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Human Genetics, 2012, 131, 581-589.	1.8	108
63	Decreased Fragile X Mental Retardation Protein Expression Underlies Amygdala Dysfunction in Carriers of the Fragile X Premutation. Biological Psychiatry, 2011, 70, 859-865.	0.7	88
64	Brief Report: Sensorimotor Gating in Idiopathic Autism and Autism Associated with Fragile X Syndrome. Journal of Autism and Developmental Disorders, 2011, 41, 248-253.	1.7	71
65	Lifetime Prevalence of Mood and Anxiety Disorders in Fragile X Premutation Carriers. Journal of Clinical Psychiatry, 2011, 72, 175-182.	1.1	162
66	Improving Fragile X-Associated Tremor/Ataxia Syndrome Symptoms With Memantine and Venlafaxine. Journal of Clinical Psychopharmacology, 2010, 30, 642-644.	0.7	26
67	Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome. Human Genetics, 2010, 128, 539-548.	1.8	30
68	Abnormal N400 word repetition effects in fragile X-associated tremor/ataxia syndrome. Brain, 2010, 133, 1438-1450.	3.7	24
69	Side Effects of Minocycline Treatment in Patients With Fragile X Syndrome and Exploration of Outcome Measures. American Journal on Intellectual and Developmental Disabilities, 2010, 115, 433-443.	0.8	90
70	A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of Medical Genetics, 2009, 46, 266-271.	1.5	354
71	Conversion disorder in women with the <i>FMR1</i> premutation. American Journal of Medical Genetics, Part A, 2009, 149A, 2501-2506.	0.7	15
72	Fragile X syndrome—From genes to cognition. Developmental Disabilities Research Reviews, 2009, 15, 333-342.	2.9	76

#	Article	IF	CITATIONS
73	A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome. Journal of Neurodevelopmental Disorders, 2009, 1, 33-45.	1.5	156
74	Fragile X: A Family of Disorders. Advances in Pediatrics, 2009, 56, 165-186.	0.5	92
75	Trial of fenobam, an mGluR5 antagonist, in adults with Fragile X Syndrome. Journal of Intellectual Disability Research, 2008, 52, 814-814.	1.2	7